These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 16304854)

  • 1. Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease (CLAP-IHD).
    Ashraf T; Ahmed M; Talpur MS; Kundi A; Faruqui AM; Jaffery AH; Fareed A
    J Pak Med Assoc; 2005 Oct; 55(10):443-8. PubMed ID: 16304854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
    Oberhänsli M; Lehner C; Puricel S; Lehmann S; Togni M; Stauffer JC; Baeriswyl G; Goy JJ; Cook S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):587-92. PubMed ID: 23177487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
    J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel.
    Sambu N; Radhakrishnan A; Curzen N
    J Cardiovasc Pharmacol; 2012 Dec; 60(6):495-501. PubMed ID: 23232787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.
    von Beckerath N; Taubert D; Pogatsa-Murray G; Schömig E; Kastrati A; Schömig A
    Circulation; 2005 Nov; 112(19):2946-50. PubMed ID: 16260639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography.
    Srimahachota S; Rojnuckarin P; Udayachalerm W; Buddhari W; Chaipromprasit J; Lertsuwunseri V; Akkawat B; Jirapattrathamrong S
    J Med Assoc Thai; 2012 Dec; 95(12):1495-500. PubMed ID: 23390778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
    Gurbel PA; Bliden KP; Butler K; Tantry US; Gesheff T; Wei C; Teng R; Antonino MJ; Patil SB; Karunakaran A; Kereiakes DJ; Parris C; Purdy D; Wilson V; Ledley GS; Storey RF
    Circulation; 2009 Dec; 120(25):2577-85. PubMed ID: 19923168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: a single-dose, randomized-sequence, open-label crossover study.
    Di Girolamo G; Czerniuk P; Bertuola R; Keller GA
    Clin Ther; 2010 Jan; 32(1):161-70. PubMed ID: 20171421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
    James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
    Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: a clinical trial.
    Müller A; Octavio J; González MY; Contreras J; Méndez G; Portillo M; Valero Z
    Am J Ther; 2010; 17(3):351-6. PubMed ID: 20019589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of laropiprant on the antiplatelet activity of co-administered clopidogrel and aspirin.
    De Kam PJ; Luo WL; Wenning L; Ratcliffe L; Sisk CM; Royalty J; Radziszewski W; Wagner JA; Lai E
    Platelets; 2014; 25(7):480-7. PubMed ID: 24206527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.
    Gladding P; Webster M; Zeng I; Farrell H; Stewart J; Ruygrok P; Ormiston J; El-Jack S; Armstrong G; Kay P; Scott D; Gunes A; Dahl ML
    JACC Cardiovasc Interv; 2008 Dec; 1(6):612-9. PubMed ID: 19463374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
    Tang FK; Lin LJ; Hua N; Lu H; Qi Z; Tang XZ
    Chin Med J (Engl); 2012 Feb; 125(4):631-8. PubMed ID: 22490487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antiplatelet effect of two clopidogrel bisulfate formulations: Plavix and generic-Egitromb.
    Komosa A; Siller-Matula JM; Kowal J; Lesiak M; Siniawski A; Mączyński M; Michalak M; Mularek-Kubzdela T; Grajek S
    Platelets; 2015; 26(1):43-7. PubMed ID: 24499166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.
    Kim SD; Kang W; Lee HW; Park DJ; Ahn JH; Kim MJ; Kim EY; Kim SW; Nam HS; Na HJ; Yoon YR
    Clin Ther; 2009 Apr; 31(4):793-803. PubMed ID: 19446152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic clopidogrel: time to substitute?
    Doll J; Zeitler E; Becker R
    JAMA; 2013 Jul; 310(2):145-6. PubMed ID: 23839745
    [No Abstract]   [Full Text] [Related]  

  • 19. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
    Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
    Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
    Kastrati A; von Beckerath N; Joost A; Pogatsa-Murray G; Gorchakova O; Schömig A
    Circulation; 2004 Oct; 110(14):1916-9. PubMed ID: 15262828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.